| |
| Your AAOS
A Message from the AAOS President About COVID-19
During this challenging time, AAOS is committed to staying out in front of the rapidly evolving COVID-19 pandemic. As you know, out of caution for our attendees’ safety and awareness that so many of you are needed in your communities, we made the difficult decision to cancel the 2020 Annual Meeting. Now, more than ever, we need to work together to ensure that you remain safe and are well-equipped to provide care to patients who require urgent or emergent surgeries. While we continue to look for ways to bring you the latest in virtual orthopaedic education and research from our Annual Meeting, we have also prioritized the development of a hub where AAOS members can easily access a wide range of relevant and credible COVID-19 resources and information.
Read the full message from Kristy L. Weber, MD, FAAOS…
Access the COVID-19 Member Resource Center… |
| |
|
|
|
| |
| Proceeding as Scheduled: Open Hearings and Business Meetings
The AAOS Bylaws require certain business to be handled in conjunction with the AAOS Annual Meeting, specifically, the Open Hearings and Business Meetings, as indicated in the Official Notice previously distributed. These matters will proceed at the scheduled date and time through a virtual platform The Open Hearings will be held on Wednesday, March 25 at 1 p.m. E.D.T. The Business Meetings will be held on Thursday, March 26 at 11:30 a.m. E.D.T. Additional details, along with information on accessing these events, will be provided in a separate communication and will be available on the AAOS website. If you have any questions, contact Donna Malert, CAE, director of governance and affiliate relations, at malert@aaos.org. |
| |
|
|
|
| |
| Online Balloting: 2020 AAOS Nominating Committee Slate
The AAOS Bylaws require certain business to be handled in conjunction with the AAOS Annual Meeting, specifically relating to the 2020 Nominating Committee slate announced to the Fellowship in November 2019. All AAOS Fellows are asked to approve the following slate of individuals to serve on the AAOS Board of Directors:
- Felix (Buddy) H. Savoie III, MD, FAAOS (La.): Second Vice-President
- Alexander Vaccaro, MD, PhD, MBA, FAAOS (Pa.): Member-at-Large (Age 45 and over)
- Matthew P. Abdel, MD, FAAOS (Minn.): Member-at-Large (Under age 45)
Voting on the Nominating Committee slate typically occurs during the Business Meeting held at the AAOS Annual Meeting. This year, we will vote online through a quick, secure, and confidential process. Balloting will open on Tuesday, March 24 at 9 a.m. E.D.T. and close on Wednesday, March 25 at 5 p.m. E.D.T. Additional details, along with the link to cast your vote, will be distributed to you before 9 a.m. E.D.T. on Tuesday, March 24. |
| |
|
|
|
| |
| COVID-19 Updates
CMS Recommends Limiting All Nonessential Adult Surgeries
The Centers for Medicare & Medicaid Services (CMS) issued recommendations for elective surgeries and nonessential medical, surgical, and dental procedures to address the COVID-19 pandemic. CMS recommends limiting these procedures in order to conserve resources and reduce the risk of exposure.
Read the CMS press release…
Read the recommendations… |
| |
|
|
|
| |
| FDA Issues Clinical Trial Guidelines Related to COVID-19
The Food and Drug Administration (FDA) released recommendations addressing clinical trial concerns amid the COVID-19 pandemic. The recommendations include implementing alternative assessment strategies performed virtually or by phone.
Read more…
Read the FDA press release…
Read the recommendations… |
| |
|
|
|
| |
| President Trump Signs COVID-19 Relief Package, Increasing State Medicaid Funding
President Donald J. Trump signed the second COVID-19 relief package from Congress. The legislation increases state Medicaid funding and ensures that insurers will not charge cost-sharing services for coronavirus testing-related services.
Read more… |
| |
|
|
|
| |
| In Other News
Study Evaluates Effect of Tranexamic Acid on Cancer Patients Undergoing Endoprosthetic Reconstruction
A retrospective study published in the March 15 issue of the Journal of the AAOS ® assessed how tranexamic acid (TXA) influences perioperative blood loss, blood transfusion rates, venous thromboembolism (VTE) occurrence, and hospital stay in patients undergoing resection of an aggressive bone tumor and endoprosthetic reconstruction. Of the 90 patients whose charts were reviewed, 34 received TXA, and 56 did not. In the TXA group, proximal femur replacement patients had a 796 mL reduction in 72-hour mean blood loss. In distal femur replacement patients who received TXA, the mean reduction was 687 mL. In the TXA group, compared to the non-TXA group, average blood transfusions decreased by 0.45 U of packed red blood cells per patient, and the transfusion rate decreased by 21.1 percent. Proximal femur replacement patients who received TXA, compared to their non-TXA counterparts, left the hospital 2.2 days earlier. TXA use did not increase the rate of VTE.
Read the abstract… |
| |
|
